Enveric Biosciences (ENVB) EBT (2010 - 2026)
Enveric Biosciences (ENVB) posted EBT of -$1.6 million for Q1 2026, down 84.34% sequentially from -$886115.0 in Q4 2025, and up 25.24% YoY from -$1.3 million in Q1 2025.
Enveric Biosciences (ENVB) EBT (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported EBT for 17 years, with the latest figure at -$1.6 million in Q1 2026.
- Quarterly EBT rose 25.24% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.9 million (up 25.64% YoY) and the FY2025 annual result came in at -$7.5 million, up 21.97% from the prior year.
- EBT retreated to -$1.6 million in Q1 2026 per ENVB's latest filing, from -$886115.0 in the prior quarter.
- Over five years, EBT peaked at $3.6 million in Q4 2023 and troughed at -$6.4 million in Q2 2023.
- A 5-year average of -$2.6 million and a median of -$2.5 million in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2024: EBT jumped 225.11% in 2023, then tumbled 186.37% in 2024.
- Over 5 years, EBT stood at -$2.9 million in 2022, then surged by 225.11% to $3.6 million in 2023, then slumped by 186.37% to -$3.1 million in 2024, then surged by 71.85% to -$886115.0 in 2025, then slumped by 84.34% to -$1.6 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$1.6 million, -$886115.0, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 81.49 Mn |
| 10 | Enveric Biosciences | 5.72 Mn | -2.57 Mn | - | -3.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.63 Mn |
| Dec 31, 2025 | -886,115.00 |
| Sep 30, 2025 | -1.87 Mn |
| Jun 30, 2025 | -2.52 Mn |
| Mar 31, 2025 | -2.18 Mn |
| Dec 31, 2024 | -3.15 Mn |
| Sep 30, 2024 | -2.08 Mn |
| Jun 30, 2024 | -1.88 Mn |
| Mar 31, 2024 | -2.46 Mn |
| Dec 31, 2023 | 3.64 Mn |
| Sep 30, 2023 | -2.82 Mn |
| Jun 30, 2023 | -6.36 Mn |
| Mar 31, 2023 | -4.68 Mn |
| Dec 31, 2022 | -2.91 Mn |
| Sep 30, 2022 | -2.48 Mn |
| Jun 30, 2022 | -4.71 Mn |
| Mar 31, 2022 | -4.80 Mn |
| Dec 31, 2021 | -50.98 Mn |
| Sep 30, 2021 | -4.25 Mn |
| Jun 30, 2021 | -3.45 Mn |